Eli Lilly on Tuesday raised its full-year profit forecast, betting on surging demand for its weight-loss treatment Zepbound ...
Eli Lilly raised its annual revenue forecast by $2 billion on Tuesday due to strong demand and a steady ramp up of production of its weight-loss treatment Zepbound and related diabetes drug Mounjaro, ...
Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise ...
Eli Lilly (NYSE: LLY) saw its net income decline by $1 billion or 16% y-o-y to $5.2 billion in 2023. This can primarily be attributed to higher acquired in-process research and development ...
Part of Eli Lilly & Co., Eli Lilly SA is a Swiss company that manufactures medicines. The private company is based in Vernier, Switzerland. ELI Lilly & Company (India) Pvt Ltd. ELI Lilly & Company ...
La performance et les perspectives de l'action Eli Lilly sont donc considérées comme stables par Jefferies, les commentaires de l'analyste soulignant la confiance dans la capacité de l'entreprise à ...
INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY), le géant mondial de l'industrie pharmaceutique, a annoncé un dividende de ...